# Phase I Clinical Trial Unit for Therapeutics Against Infectious Diseases: Evaluation of Therapeutics for MERS-CoV

> **NIH NIH N01** · DYNPORT VACCINE COMPANY, LLC · 2021 · $3,485

## Abstract

The Phase I Clinical Trial Units provide a vehicle for the investigation of new therapeutic and immunomodulatory agents for the treatment of infectious disease.

## Key facts

- **NIH application ID:** 10329654
- **Project number:** 272201500005I-P00007-27200003-1
- **Recipient organization:** DYNPORT VACCINE COMPANY, LLC
- **Principal Investigator:** DAVID SHUMWAY
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $3,485
- **Award type:** —
- **Project period:** 2016-08-23 → 2019-12-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10329654

## Citation

> US National Institutes of Health, RePORTER application 10329654, Phase I Clinical Trial Unit for Therapeutics Against Infectious Diseases: Evaluation of Therapeutics for MERS-CoV (272201500005I-P00007-27200003-1). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10329654. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*